Gilead loses its challenge to a pair of U.S. patents for an HIV prevention pill
Although a Gilead challenge to another set of CDC patents has not been decided, the ruling comes amid a bruising fight between the company and the government.
In a setback to Gilead Sciences (GILD), a federal panel rejected its bid to invalidate a pair of patents owned by the U.S. government for using the Truvada pill to prevent HIV, a drug that has sparked controversy due to its cost and the extent to which taxpayer dollars funded crucial research.
The Patent Trial and Appeals Board ruled that Gilead failed to demonstrate it was likely to win its and here is ).
